Filing summary
Entity discrepancy: The request identifies Neurogene Inc., but the supplied Form 10-Q is for Aquinox Pharmaceuticals, Inc. This summary reflects the filing provided, not Neurogene.
Business context and reporting period
The filing covers the quarter ended September 30, 2015, and is unaudited. Aquinox was a clinical-stage pharmaceutical company focused on SHIP1-targeting therapies. Its lead candidate, AQX-1125, was being developed primarily for bladder pain syndrome/interstitial cystitis (BPS/IC). The company reported no revenue.
Financial results and liquidity
All amounts are U.S. dollars. Financial statement amounts below are in millions unless stated otherwise.
- Revenue: None to date.
- Q3 2015: Operating expenses were $4.9 million, down from $6.3 million in Q3 2014. Net loss was $5.0 million versus $6.3 million; basic and diluted loss per share was $0.43 versus $0.59.
- First nine months of 2015: Operating expenses were $15.7 million, up from $14.6 million in the comparable 2014 period. Net loss was $16.2 million versus $15.9 million; loss per share was $1.46 versus $1.97.
- Expenses: Nine-month research and development expense was $11.9 million, approximately flat year over year. General and administrative expense rose to $3.9 million from $2.8 million, mainly reflecting public-company, personnel and legal costs.
- Cash flow: Operating activities used $16.8 million in the first nine months of 2015, compared with $10.8 million in 2014. Financing activities provided $93.1 million, primarily from the September public offering; investing activities provided $18.1 million, primarily from investment maturities.
- Liquidity and debt: At September 30, cash and cash equivalents were $109.4 million and short-term investments were $8.0 million, totaling $117.4 million in cash, equivalents and short-term investments. Working capital was $114.1 million. Total liabilities were $4.0 million, including $3.9 million of current liabilities and $0.1 million of warrant liabilities; the prior bank loan had been repaid in 2014. Management said existing resources were expected to fund operations for at least 12 months.
- Margins: Not meaningful because the company had no revenue. The filing reports no operating profit.
Material changes and notable items
- On September 15, 2015, Aquinox completed a public offering of 6.325 million shares at $15.50 per share, generating approximately $98.0 million gross and $92.0 million net proceeds after offering costs. Shares outstanding increased to 17,211,986 at September 30, from 10,695,108 at year-end 2014.
- Q3 R&D expense declined as final activities for the Leadership and Flagship trials wound down; nine-month R&D was slightly higher due in part to the Kinship trial.
- Stock-based compensation was $1.1 million for the first nine months, versus $0.6 million in 2014. The company recorded a $0.4 million foreign-exchange loss for the period.
Outlook, clinical developments and risks
- In the Leadership Phase 2 BPS/IC trial, the primary pain endpoint favored AQX-1125 but did not reach statistical significance (p=0.061). Certain secondary endpoints were statistically significant. The company planned to discuss pivotal-trial design with the FDA in Q4 2015 and anticipated a first pivotal trial in 2016, subject to regulatory input.
- The Flagship Phase 2 COPD trial failed to show efficacy; Aquinox said it was not planning further AQX-1125 development for COPD. Results announced November 2, 2015, after quarter-end, showed the Kinship atopic dermatitis trial missed its primary endpoint and did not warrant further development for that indication.
- Management expected losses and expenses to continue and R&D spending to increase as BPS/IC development advanced. The company anticipated needing substantial future financing; additional capital could dilute shareholders or be unavailable on acceptable terms.
- Key risks include the failed or inconclusive Phase 2 results, the unvalidated SHIP1 target, uncertain dose and pivotal-trial design, regulatory and clinical-trial risk, reliance on third-party manufacturers and CROs, and the absence of product revenue. The filing also cites animal toxicology findings involving gastrointestinal ulcerations and ocular effects, although clinical trials to date generally described AQX-1125 as well tolerated.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective at a reasonable assurance level; it also disclosed prior significant deficiencies in internal controls that it would need to address for future Section 404 reporting.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Aquinox Pharmaceuticals, Inc., not Neurogene Inc.
- Review the full Leadership trial data, FDA feedback, and whether Phase 2 completion and the proposed pivotal-trial plan were accepted.
- Assess the implications of the September offering, dilution, cash burn, and the assumptions underlying the stated 12-month-plus runway.
- Check subsequent clinical and regulatory disclosures, particularly the post-quarter Kinship result and any changes to AQX-1125’s BPS/IC development plans.
- Review progress in remediating the previously identified internal-control deficiencies and the sensitivity of the warrant-liability valuation.